Nivolumab+AVD improves progression-free survival in advanced-stage Hodgkin lymphoma
1. This randomized controlled trial found that in patients with newly diagnosed stage III or IV Hodgkin lymphoma, treatment with ...
1. This randomized controlled trial found that in patients with newly diagnosed stage III or IV Hodgkin lymphoma, treatment with ...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. Significantly more patients in the imetelstat group achieved RBC transfusion independence at 8 weeks after treatment compared to placebo. ...
1. This prospective study found that low eosinophil counts (< .01 g/L) were significantly associated with acute bacterial infection in ...
1. In this randomized controlled trial, upadacitinib resulted in higher remission rates for patients with Crohn’s disease compared to a ...
Click to read this study in The Lancet Oncology.
1. Median event-free survival in the liso-cel group was significantly greater than in the standard-of-care group (10.1 months vs. 2.3 ...
Click to read the study in JAMA Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.